SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is seeing significant downward pressure driven by market apprehension surrounding Donald Trump's extended and often incoherent public address, where his discussion of tariffs and Greenland policy raises concerns about global trade stability. Community sentiment is deeply divided, with many expressing alarm over potential economic repercussions while a subset anticipates a swift "buy the dip" recovery from the current volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst significant market volatility, fueled by discussions surrounding former President Trump's public statements on geopolitical issues, including Greenland and proposed tariffs, which are sparking international concern and market reactions. Community chatter is highly polarized, with supporters pointing to a new digital token initiative as a potential short squeeze catalyst, while critics link the former President's rhetoric to broader market instability and question the stock's underlying value.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a focal point of market discussion after recently upgrading its bid for Warner Bros. Discovery assets to an all-cash offer, a strategic move generating debate about its long-term growth prospects ahead of the upcoming earnings report. Community sentiment is sharply divided, with many seeing the stock as oversold and ripe for a rebound, while others express caution regarding the deal's implications and broader market headwinds.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is highly active amidst intense discussions fueled by geopolitical developments, specifically related to rhetoric from Davos concerning Greenland and potential tariffs impacting European allies. Community sentiment is bifurcated, with many anticipating continued declines from global instability and upcoming interest rate decisions, while a significant portion of traders are actively buying the dip, expecting a customary market rebound despite the contentious headlines.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple (AAPL) is currently experiencing highly polarized community sentiment, with many expressing frustration over its recent price decline, perceived lack of AI innovation, and broader market weakness. However, a strong counter-narrative highlights the stock as deeply oversold with historically low RSI levels, presenting a significant "buy the dip" opportunity ahead of its anticipated strong holiday quarter earnings. Geopolitical tensions and ongoing tariff discussions are further fueling volatility and shaping investor outlook on the tech giant.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending dramatically after announcing promising Phase 1 clinical trial results for its oral drug, soquelitinib, treating moderate to severe atopic dermatitis with strong efficacy and a favorable safety profile. The market is actively discussing the drug's potential, especially for patients resistant to current therapies, driving speculation of significant upside and a short squeeze, though some caution against the early trial stage and potential dilution.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant technology, widely seen by the community as a validation of its core platform. This development has fueled expectations of further partnerships and a potential short squeeze, with many closely watching how management addresses continued activist investor pressure for enhanced shareholder value.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing a surge in attention following a pivotal FDA meeting for its ANKTIVA bladder cancer treatment, where regulators reportedly indicated no requirement for new clinical trials and requested additional data for submission within 30 days. This news has ignited strong community discussion, with investors buzzing about a potential short squeeze and highlighting ANKTIVA's broad therapeutic promise across various cancer indications. The stock's robust performance amid a challenging market is drawing significant interest, as many anticipate further positive developments and substantial long-term growth for this biotech company.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

ProShares Ultra VIX Short-Term Futures ETF ($UVXY) is actively trending as traders weigh potential market volatility driven by discussions surrounding recent geopolitical developments, including international tariffs, and the anticipated Bank of Japan rate hike. The community is sharply divided, with many actively debating short positions on $UVXY due to its inherent decay, while others anticipate a volatility spike, expressing frustration over its subdued movement despite broader market fluctuations.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding is trending following news of its strategic acquisition of a luxury wine authentication and trading business, diversifying its market beyond caviar. This has ignited significant discussion among traders, with many anticipating further price movement and highlighting strong volume, while others express concerns about a recent public offering and potential dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LakeShore Biopharma Co., Ltd (LSB) on Thursday announced that its board of directors has received a revised preliminary non-binding proposal letter from a consortium to acquire all of the outstanding ordinary shares of the company in an all-cash transaction for $0.86 per ordinary share.The consortium is comprised of Oceanpine Investment Fund II LP, Oceanpine Capital Inc., and Crystal Peak Investment Inc. Members of the consortium currently beneficially own in aggregate approximately 52.1% of the company's issued and outstanding ordinary shares.The revised proposal letter, dated August 26, revises the preliminary non-binding proposal letter dated August 18, previously received from Oceanpine Capital.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LSB">LSB stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.LakeShore <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-receipt-of-a-revised-preliminary-non-binding-proposal-to-acquire-the-company-and-formation-of-special-committee-302541021.html">said</a> its board has formed a special committee consisting of its three independent directors, Adam Zhao, Thomas Xue, and Chunyang Shao, to evaluate and consider the revised proposal letter and transaction.The company has not made any decisions regarding its response to the proposal, it said, while adding that there is no assurance that a definitive offer will be made or an agreement executed.LakeShore said that the proposed purchase price per share of $0.86, which represents a premium of about 9% from the stock’s closing price on Wednesday, remains unchanged from the original proposal.The members of the consortium, however, have entered into an agreement to vote all of their shares in favor of the proposed transaction. They also do not intend to sell their shares to any third party or support any competing bid while remaining members of the consortium, LakeShore said.LSB stock is down by 77% this year and by 82% over the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-gdp-3-3-in-q2-revised-upwards-from-3/chs6JFbRdmZ">GDP Grows At 3.3% In Q2, Economy Expands At A Faster Clip Than Previously Estimated</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

LakeShore Biopharma Receives Revised Proposal To Acquire Company

The company said the revised preliminary non-binding letter proposes the acquisition of all outstanding ordinary shares in an all-cash transaction for $0.86 apiece.

Equity

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee LakeShore Biopharma Announces Receipt of a Revised...

LakeShore Biopharma Co. (LSB) on Monday said that its board received a preliminary non-binding proposal letter to acquire all of the outstanding ordinary shares of the company for $0.86 per share.The proposal from Oceanpine Investment Fund II LP and Oceanpine Capital Inc. was dated August 18 and is for all shares not currently owned by Oceanpine Capital, the company said. The price of $0.86 represents a premium of 10.3% to the stock’s closing price on August 15.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-receipt-of-a-preliminary-non-binding-proposal-to-acquire-the-company-302532192.html">said</a> that the board will carefully review and evaluate the proposal to determine the future course of action. However, the board has not made any decisions on the proposal, and there is no assurance that any agreement will be executed, it added.On Stocktwits, retail sentiment about <a href="https://stocktwits.com/symbol/LSB">LakeShore</a> trended in the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Shares of the company traded 1% higher in the pre-market session at the time of writing.The proposed transaction will be funded with rollover equity and available cash on hand and will not be subject to a financing condition, Oceanpine said in its letter. “While we are fully prepared to work collaboratively with the Board to pursue the proposed transaction in a timely manner, we are open to exploring potential alternative structures of the Proposed Transaction to expedite the process of delivering value to the Company's shareholders,” Oceanpine said in its letter.LakeShore Biopharma operates in China, Singapore, and the Philippines. Its main product is a freeze-dried human rabies vaccine.LSB stock is down by 77% this year and by about 83% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tonix-pharma-stock-rises-pre-market-after-fda-approval-for-drug/chsO9FfRdXb">This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

LakeShore Biopharma Just Got An Acquisition Proposal From Oceanpine Capital: More Details Inside 

The offer price of $0.86 represents a premium of 10.3% to the company's last closing price on August 15.

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

LakeShore Biopharma Co Ltd.

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

LSB
LakeShore Biopharma Co Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest LSB News

LSBLakeShore Biopharma Co Ltd.